ALLENEDRUG Targeting Type 2 Diabetes with Allene-containing Molecules Using a C-N Bond Cleavage Tool
- Coordinator
- Universidad Autonoma De Madrid, Spain
- Runs
- 1 July 2025 to 31 December 2026
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101213797
What the project is doing
In the project's own words, from its summary on CORDIS.
Type 2 Diabetes is a chronic disease affecting more than 450 million people world-wide and is still an unmet medical need. PPAR´s(Peroxisome Proliferator-Activated Receptors) and G-protein-coupled receptors (GPCR) FFARs (Free Fatty Acid Receptors) are wellclinical validated targets for type-2 diabetes. Although selective GPR40 agonists have reached clinical phase III, the trials wererecently terminated due to signs of liver toxicity in patients.
ALLENEDRUG is designed to provide a new chemical series of GPR40ligands aiming to bring a safer type-2 diabetes therapy. To achieve this goal, we will use a synthetic tool developed in our laboratoryto prepare enantiomerically enriched allenes through a selective C-N bond cleavage. This ERC-PoC will allow us to test the newchemical series as potential GPR40 agonists and to get insight into a SAR (Structure Activity Relationship) correlation with liver toxicityin order to compare the new molecules prepared in this proposal with those currently in clinical phase III trials.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universidad Autonoma De Madrid | Madrid | Spain | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI